semaglutide and parkinson's disease Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine Live Updates on Semaglutide's Current

Their responses concern fiscal years 2024 and 2025, which covers a period of uncertainty for the programs

Cagrilintide development and structure What cagrilintide is: Synthetic long-acting amylin analog Modified 37-amino acid sequence Developed by Novo Nordisk Designed specifically for obesity treatment Based on natural amylin but optimized Key structural modifications: Amino acid substitutions for stability Prevented amyloid aggregation (major improvement) Extended half-life to ~7 days (vs minutes for natural amylin) Maintained receptor binding and activity Better pharmacokinetic profile Development timeline: Early 2010s: Initial development 2019-2020: Phase 2 trials (OASIS) 2021-2023: Phase 3 trials (REDEFINE as CagriSema) 2024-2025: FDA submission expected Likely approval 2025-2026 Why cagrilintide is breakthrough: First truly long-acting amylin agonist Weekly dosing (vs pramlintide 2-3x daily) Designed for weight loss (not diabetes adaptation) Proven synergy with semaglutide (CagriSema) Approaching availability Cagrilintide weight loss results Monotherapy clinical data (OASIS trials): Duration: 26-68 weeks Dose: 2.4mg weekly (standard) Average weight loss: 10-12% Some participants: 15%+ loss Well-tolerated at therapeutic dose Weight loss by dose: 0.6mg weekly: ~6% weight loss 1.2mg weekly: ~8% weight loss 2.4mg weekly: ~10% weight loss 4.5mg weekly: ~12% weight loss (higher side effects) CagriSema combination (cagrilintide + semaglutide): Both at 2.4mg weekly Average weight loss: 15.6% (REDEFINE-1) Excellent responders: 20-25% 50% more than semaglutide alone Game-changing results Real-world expectations: See our comprehensive cagrilintide weight loss guide

It causes terminal hairs that contribute to the appearance of hair fullness to become vellus hairs (i.e., peach fuzz hairs), ultimately leading to hair thinning, a process known as hair follicle miniaturization

Analysis of commercial claims data covering approximately 50 million insured lives found GLP-1 users experienced: 44% fewer major cardiovascular-related hospitalizations 69% improvement in medical spend growth among diabetes-related GLP-1 users over 30 months 37% improvement in medical spend growth among weight-loss GLP-1 users over 18 months Researchers have also observed positive trends related to inflammatory conditions, cardiovascular disease, and other chronic health concerns

Which Is Better For You